12/8/2023 0 Comments Bio rad qx600On the supply-chain front, Bio-Rad is expected to have made progress in reducing the elevated Life Science backlog position throughout the second quarter. The overall performance in Russia is likely to have dented the company’s quarterly sales due to the further tightening of sanctions. Geographically, we anticipate the Life Science segment to have posted core organic revenue growth in the Americas and Europe similar to the first quarter. In the first quarter, Bio-Rad experienced softness in smaller biopharma companies and a tough comparison for the process chromatography franchise related to a very large customer order in the first quarter of 2022, which resulted in a year-over-year decline in revenues. Quoteĭespite the sales slowdown in the last quarter, the process chromatography franchise is expected to have witnessed growth, backed by the solid and consistent underlying demand for the business. price-eps-surprise | Bio-Rad Laboratories, Inc. Price and EPS Surpriseīio-Rad Laboratories, Inc. The addition is likely to have expanded Bio-Rad’s oncology assay menu for Droplet Digital PCR, which buoys optimism.īio-Rad Laboratories, Inc. This assay kit includes an automated analysis package and enables clinical researchers to assess microsatellite instability status across multiple cancers. On the last earnings call, the company highlighted the expected launch of the ddPCR microsatellite instability kit toward the end of the second quarter. During the first quarter months, the demand for the new QX600 Droplet Digital PCR (ddPCR) system and customer acceptance has been remarkable, which we expect to have significantly benefited BIO’s top line in the to-be-reported quarter. Factors at Playīio-Rad’s Life Science segment is likely to have witnessed year-over-year currency-neutral core revenue growth in the second quarter, driven by qPCR products, Western loading and digital PCR. Let’s look at how things have shaped up before this announcement. Bio-Rad beat earnings estimates in three of the trailing four quarters and missed the same in one, the average surprise being 9.21%. The company posted adjusted earnings per share (EPS) of $3.34 in the last reported quarter, which beat the Zacks Consensus Estimate by 3.09%. ( BIO Quick Quote BIO - Free Report) is set to release second-quarter 2023 results on Aug 3 after the closing bell. Save my name, email, and website in this browser for the next time I comment.Bio-Rad Laboratories, Inc. “With the launch of the QX600 system, we’re excited to bring advanced multiplexing and unmatched sensitivity to molecular oncology investigators engaged in everything from biomarker discovery to clinical trials and patient monitoring of MRD.”īIO-RAD, ddPCR, Droplet Digital, QXDx, QX200 and QX600 are trademarks of Bio-Rad Laboratories, Inc. “The QX200 system has been an outstanding workhorse, cited in over 6,300 publications with nearly 1,000 of those focused on oncology,” said Stephen Kulisch, vice president of marketing for Bio-Rad’s Digital Biology Group. “Combining high multiplexing power with the proven sensitivity and absolute quantification of ddPCR technology will allow us to obtain greater volumes of high-quality clinical research data without burdening patients, ultimately driving precision medicine forward,” said Boris Wong, MSc, a translational researcher at the University of Melbourne who participated in beta testing for the QX600 ddPCR System earlier this year. The introduction of the QX600 ddPCR System expands the company’s family of QX platforms, which currently includes the CE Marked IVDR compliant QX200 system, the FDA-cleared QXDx system and the high-throughput, fully automated QX ONE system. We also expect that this will drive the development of novel, multiplexed assays that were not possible before.” “We anticipate leveraging this tool for rare variant detection as a method of analyzing multiple mutations for MRD and therapeutic response testing for our blood-based oncology offerings. “The QX600 is an incredibly powerful instrument,” said Gary Pestano, Ph.D., chief development officer at Biodesix, Inc., who also served as a beta tester. One such collaborator is already planning ways to apply the new QX600 ddPCR System. Maintaining Bio-Rad’s best-in-class ddPCR technology, this platform utilizes the same droplet generation and processing protocols as the QX200 system, enabling thousands of current customers to easily adopt its advanced multiplexing capabilities. Launched late last year, it boasts six color detectors capable of quantifying 12 targets per well, a simple user workflow, and powerful data analysis. Bio-Rad Laboratories, a company specializing in life science research and clinical diagnostic products, is accelerating measurable residual disease (MRD) research through more than a half dozen collaborations with institutions and companies leveraging its new QX600 Droplet Digital PCR System.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |